Pharmacokinetics and Tissue Distribution of Recombinant Human Transforming Growth Factor Beta1 After Topical and Intravenous Administration in Male Rats
- 1 January 1994
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 11 (2) , 213-220
- https://doi.org/10.1023/a:1018995005775
Abstract
Recombinant human transforming growth factor beta (rhTGF-β1) enhances the healing process after topical application to various animal wound models. A detailed pharmacokinetic and tissue distribution study was performed to support the clinical development of rhTGF-β1 for wound healing indications. Rats received radioiodinated or unlabeled rhTGF-β1 as an intravenous (iv) bolus or as a topical formulation applied to a full thickness wound. Plasma concentrations of TGF-β1 were estimated from TCA-precipitable radioactivity or were measured by ELISA. Following iv administration, the initial half-life was rapid (1 was used. The terminal half-life was long (163 min) when the test material was radioiodinated and administered as a trace dose and relatively short (≤61 min) when given at high doses and assayed by ELISA. Analysis of plasma radioactivity by SDS-PAGE revealed a time-dependent clearance of the 25-kDa parent molecule without a significant appearance of lower molecular weight radiolabeled metabolites. The majority of the radioactivity was associated with highly perfused organs, known iodide elimination pathways, and the thyroid at 1 and 8 hr after iv injection. After topical administration of a high dose (0.8 mg/kg), no immunoreactive TGF-β1 was detectable in plasma samples taken over a 48-hr period. However, trace amounts (≤0.05 ng/mL) of acid-precipitable radioactivity were detected in plasma after topical application of [125I]rhTGF-β1 (1 µg/kg, 126 µCi/kg). A significant portion (35%) of the [125I]rhTGF-β1 persisted intact (25 kDa) at the wound site 24 hr after application. In conclusion, rhTGF-β1 was rapidly cleared after iv bolus administration and distributed primarily to the liver, lungs, kidney, and spleen. Little systemic exposure was observed after applying a single topical dose of rhTGF-β1 to a wound, and the intact molecule persisted at the wound site.Keywords
This publication has 24 references indexed in Scilit:
- Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution.Journal of Clinical Investigation, 1990
- The Transforming Growth Factor-beta FamilyAnnual Review of Cell Biology, 1990
- Immunodetection and quantitation of the two forms of transforming growth factor‐beta (TGF‐β1 and TGF‐β2) secreted by cells in cultureJournal of Cellular Physiology, 1989
- Accelerated Healing of Incisional Wounds in Rats Induced by Transforming Growth Factor-βScience, 1987
- Some recent advances in the chemistry and biology of transforming growth factor-beta.The Journal of cell biology, 1987
- Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro.The Journal of cell biology, 1987
- Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.The Journal of Experimental Medicine, 1987
- Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cellsNature, 1985
- Purification and properties of a type .beta. transforming growth factor from bovine kidneyBiochemistry, 1983
- Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the dataJournal of Pharmacokinetics and Biopharmaceutics, 1976